{"id":41229,"date":"2025-09-12T13:37:51","date_gmt":"2025-09-12T05:37:51","guid":{"rendered":"https:\/\/flcube.com\/?p=41229"},"modified":"2025-09-12T13:37:52","modified_gmt":"2025-09-12T05:37:52","slug":"fibrox-therapeutics-secures-ind-approval-for-fibrocell-in-lumbar-disc-degeneration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41229","title":{"rendered":"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration"},"content":{"rendered":"\n<p>Shanghai\u2011based <strong>FibroX Therapeutics<\/strong> announced that its <strong>investigational new drug (IND)<\/strong> application for <strong>FibroCell<\/strong>, an allogeneic human fibroblast injection, has received approval from the <strong>China Food and Drug Administration (CFDA)<\/strong> for the treatment of <strong>moderate\u2011to\u2011severe lumbar disc degenerative disease<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-fibrocell-brings-to-the-back-pain-market\">What FibroCell Brings to the Back\u2011Pain Market<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class cell\u2011based therapy<\/strong> that converts degenerated nucleus pulposus cells into fibrous cells, directly addressing the root cause of disc degeneration.<\/li>\n\n\n\n<li><strong>Clinical advantage<\/strong> for patients in early\u2011to\u2011mid stages of disc degeneration, where current surgical or pharmacologic options are limited.<\/li>\n\n\n\n<li><strong>Dual mechanism of action<\/strong>:<\/li>\n\n\n\n<li><em>Anti\u2011inflammatory<\/em>: Suppresses local inflammation within the disc.<\/li>\n\n\n\n<li><em>Mechanical reinforcement<\/em>: Enhances disc stiffness through fibrosis, delaying disease progression.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-delivery-and-safety\">Delivery and Safety<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Administered via a <strong>minimally invasive injection<\/strong> into the annulus fibrosus, reducing the risk of trauma and post\u2011procedural complications.<\/li>\n\n\n\n<li>Early\u2011stage clinical data show <strong>rapid restoration of disc structure<\/strong> and <strong>persistent relief of lower\u2011back pain<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-and-commercial-outlook\">Regulatory and Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IND approval<\/strong> paves the way for <strong>Phase\u202fI\/II clinical trials<\/strong> to confirm safety and efficacy in a larger cohort.<\/li>\n\n\n\n<li>If successful, FibroCell could become the first FDA\u2011qualified cell therapy for lumbar disc degeneration, opening a <strong>multi\u2011billion\u2011dollar market<\/strong> for regenerative back\u2011pain solutions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai\u2011based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41231,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,4346],"class_list":["post-41229","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-fibrox-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai\u2011based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic human fibroblast injection, has received approval from the China Food and Drug Administration (CFDA) for the treatment of moderate\u2011to\u2011severe lumbar disc degenerative disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41229\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration\" \/>\n<meta property=\"og:description\" content=\"Shanghai\u2011based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic human fibroblast injection, has received approval from the China Food and Drug Administration (CFDA) for the treatment of moderate\u2011to\u2011severe lumbar disc degenerative disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41229\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-12T05:37:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-12T05:37:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration\",\"datePublished\":\"2025-09-12T05:37:51+00:00\",\"dateModified\":\"2025-09-12T05:37:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1202.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"FibroX Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41229#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41229\",\"name\":\"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1202.webp\",\"datePublished\":\"2025-09-12T05:37:51+00:00\",\"dateModified\":\"2025-09-12T05:37:52+00:00\",\"description\":\"Shanghai\u2011based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic human fibroblast injection, has received approval from the China Food and Drug Administration (CFDA) for the treatment of moderate\u2011to\u2011severe lumbar disc degenerative disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41229\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1202.webp\",\"width\":1080,\"height\":608,\"caption\":\"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41229#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai\u2011based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic human fibroblast injection, has received approval from the China Food and Drug Administration (CFDA) for the treatment of moderate\u2011to\u2011severe lumbar disc degenerative disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41229","og_locale":"en_US","og_type":"article","og_title":"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration","og_description":"Shanghai\u2011based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic human fibroblast injection, has received approval from the China Food and Drug Administration (CFDA) for the treatment of moderate\u2011to\u2011severe lumbar disc degenerative disease.","og_url":"https:\/\/flcube.com\/?p=41229","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-12T05:37:51+00:00","article_modified_time":"2025-09-12T05:37:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41229#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41229"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration","datePublished":"2025-09-12T05:37:51+00:00","dateModified":"2025-09-12T05:37:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41229"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41229#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1202.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","FibroX Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41229#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41229","url":"https:\/\/flcube.com\/?p=41229","name":"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41229#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41229#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1202.webp","datePublished":"2025-09-12T05:37:51+00:00","dateModified":"2025-09-12T05:37:52+00:00","description":"Shanghai\u2011based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic human fibroblast injection, has received approval from the China Food and Drug Administration (CFDA) for the treatment of moderate\u2011to\u2011severe lumbar disc degenerative disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41229#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41229"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41229#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1202.webp","width":1080,"height":608,"caption":"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41229#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41229"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41229\/revisions"}],"predecessor-version":[{"id":41232,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41229\/revisions\/41232"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41231"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}